Cargando…
The use of CrossMAb technology for the generation of bi- and multispecific antibodies
The major challenge in the generation of bispecific IgG antibodies is enforcement of the correct heavy and light chain association. The correct association of generic light chains can be enabled using immunoglobulin domain crossover, known as CrossMAb technology, which can be combined with approache...
Autores principales: | Klein, Christian, Schaefer, Wolfgang, Regula, Jörg T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968094/ https://www.ncbi.nlm.nih.gov/pubmed/27285945 http://dx.doi.org/10.1080/19420862.2016.1197457 |
Ejemplares similares
-
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins
por: Surowka, Marlena, et al.
Publicado: (2021) -
DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity
por: Sustmann, Claudio, et al.
Publicado: (2019) -
Variable heavy–variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly
por: Regula, Joerg Thomas, et al.
Publicado: (2018) -
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
por: Regula, Jörg T, et al.
Publicado: (2016) -
Next generation Fc scaffold for multispecific antibodies
por: Estes, Bram, et al.
Publicado: (2021)